Neoadjuvant chemotherapy with or without concurrent hormone therapy in estrogen receptor-positive breast cancer

Nacedrandomized multicenter phase II trial

Kumi Sugiu, Takayuki Iwamoto, Catherine M. Kelly, Naoki Watanabe, Takayuki Motoki, Mitsuya Itoh, Shoichiro Ohtani, Kenji Higaki, Takako Imada, Takeshi Yuasa, Masako Omori, Hiroshi Sonobe, Toshiyoshi Fujiwara, Junji Matsuoka

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%; 2/16) and the chemotherapy alone group (8.3%; 1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (/>=0.035), but not in the chemotherapy-alone group (/>=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.

Original languageEnglish
Pages (from-to)291-299
Number of pages9
JournalActa Medica Okayama
Volume69
Issue number5
Publication statusPublished - 2015

Fingerprint

Chemotherapy
Estrogen Receptors
Hormones
Breast Neoplasms
Drug Therapy
Neoadjuvant Therapy
Tumors
Goserelin
Therapeutics
Epirubicin
Aromatase Inhibitors
Group Psychotherapy
Paclitaxel
Fluorouracil
Cyclophosphamide
Neoplasms

Keywords

  • Breast cancer
  • Concurrent hormone therapy
  • Estrogen receptor positive
  • Neoadjuvant chemotherapy
  • Tumor response

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Neoadjuvant chemotherapy with or without concurrent hormone therapy in estrogen receptor-positive breast cancer : Nacedrandomized multicenter phase II trial. / Sugiu, Kumi; Iwamoto, Takayuki; Kelly, Catherine M.; Watanabe, Naoki; Motoki, Takayuki; Itoh, Mitsuya; Ohtani, Shoichiro; Higaki, Kenji; Imada, Takako; Yuasa, Takeshi; Omori, Masako; Sonobe, Hiroshi; Fujiwara, Toshiyoshi; Matsuoka, Junji.

In: Acta Medica Okayama, Vol. 69, No. 5, 2015, p. 291-299.

Research output: Contribution to journalArticle

Sugiu, K, Iwamoto, T, Kelly, CM, Watanabe, N, Motoki, T, Itoh, M, Ohtani, S, Higaki, K, Imada, T, Yuasa, T, Omori, M, Sonobe, H, Fujiwara, T & Matsuoka, J 2015, 'Neoadjuvant chemotherapy with or without concurrent hormone therapy in estrogen receptor-positive breast cancer: Nacedrandomized multicenter phase II trial', Acta Medica Okayama, vol. 69, no. 5, pp. 291-299.
Sugiu, Kumi ; Iwamoto, Takayuki ; Kelly, Catherine M. ; Watanabe, Naoki ; Motoki, Takayuki ; Itoh, Mitsuya ; Ohtani, Shoichiro ; Higaki, Kenji ; Imada, Takako ; Yuasa, Takeshi ; Omori, Masako ; Sonobe, Hiroshi ; Fujiwara, Toshiyoshi ; Matsuoka, Junji. / Neoadjuvant chemotherapy with or without concurrent hormone therapy in estrogen receptor-positive breast cancer : Nacedrandomized multicenter phase II trial. In: Acta Medica Okayama. 2015 ; Vol. 69, No. 5. pp. 291-299.
@article{40c80a4552384690ba95cd5da2e5996d,
title = "Neoadjuvant chemotherapy with or without concurrent hormone therapy in estrogen receptor-positive breast cancer: Nacedrandomized multicenter phase II trial",
abstract = "Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5{\%}; 2/16) and the chemotherapy alone group (8.3{\%}; 1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (/>=0.035), but not in the chemotherapy-alone group (/>=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.",
keywords = "Breast cancer, Concurrent hormone therapy, Estrogen receptor positive, Neoadjuvant chemotherapy, Tumor response",
author = "Kumi Sugiu and Takayuki Iwamoto and Kelly, {Catherine M.} and Naoki Watanabe and Takayuki Motoki and Mitsuya Itoh and Shoichiro Ohtani and Kenji Higaki and Takako Imada and Takeshi Yuasa and Masako Omori and Hiroshi Sonobe and Toshiyoshi Fujiwara and Junji Matsuoka",
year = "2015",
language = "English",
volume = "69",
pages = "291--299",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "5",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy with or without concurrent hormone therapy in estrogen receptor-positive breast cancer

T2 - Nacedrandomized multicenter phase II trial

AU - Sugiu, Kumi

AU - Iwamoto, Takayuki

AU - Kelly, Catherine M.

AU - Watanabe, Naoki

AU - Motoki, Takayuki

AU - Itoh, Mitsuya

AU - Ohtani, Shoichiro

AU - Higaki, Kenji

AU - Imada, Takako

AU - Yuasa, Takeshi

AU - Omori, Masako

AU - Sonobe, Hiroshi

AU - Fujiwara, Toshiyoshi

AU - Matsuoka, Junji

PY - 2015

Y1 - 2015

N2 - Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%; 2/16) and the chemotherapy alone group (8.3%; 1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (/>=0.035), but not in the chemotherapy-alone group (/>=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.

AB - Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%; 2/16) and the chemotherapy alone group (8.3%; 1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (/>=0.035), but not in the chemotherapy-alone group (/>=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.

KW - Breast cancer

KW - Concurrent hormone therapy

KW - Estrogen receptor positive

KW - Neoadjuvant chemotherapy

KW - Tumor response

UR - http://www.scopus.com/inward/record.url?scp=84947942572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947942572&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 291

EP - 299

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 5

ER -